Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 34 of 34 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02286687	Phase II	Talazoparib	Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	Active, not recruiting	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Active, not recruiting	USA \| CAN \| AUS	1
NCT03601923	Phase II	Niraparib	Niraparib in Patients With Pancreatic Cancer	Active, not recruiting	USA	0
NCT04052555	Phase I	Berzosertib	Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer	Active, not recruiting	USA	0
NCT02476968	FDA approved	Olaparib	To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)	Completed	POL \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| BGR	0
NCT02677038	Phase II	Olaparib	Olaparib in Treating Patients With Stage IV Pancreatic Cancer	Completed	USA	0
NCT02873975	Phase II	Prexasertib	A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency	Completed	USA	0
NCT03061188	Phase I	Nivolumab + Veliparib	Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes	Completed	USA	0
NCT03207347	Phase II	Niraparib	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Completed	USA	0
NCT03318445	Phase I	Rucaparib Irinotecan + Rucaparib	Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair	Completed	USA	0
NCT03413995	Phase II	Rucaparib	Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)	Completed	USA	0
NCT03448718	Phase II	Olaparib	Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	Completed	USA	0
NCT03718091	Phase II	Berzosertib	M6620 (VX-970) in Selected Solid Tumors	Completed	USA	0
NCT04187833	Phase II	Nivolumab + Talazoparib	Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes	Completed	USA	0
NCT04288687	Phase II	Niraparib	A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects	Completed	USA	0
NCT05986071	Phase Ib/II	Fulvestrant + M1774	I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX)	Not yet recruiting	FRA	0
NCT02029001	Phase II	Durvalumab + Tremelimumab Olaparib Nilotinib	Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus)	Recruiting	FRA	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT03375307	Phase II	Olaparib	Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes	Recruiting	USA	0
NCT04042831	Phase II	Olaparib	Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations	Recruiting	USA	0
NCT04992013	Phase II	Niraparib	Niraparib in Tumors Metastatic to the CNS	Recruiting	USA	0
NCT05498272	Phase II	Leuprolide + Olaparib Goserelin + Olaparib Olaparib + Triptorelin	Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)	Recruiting	USA	0
NCT05566574	Phase Ib/II	RP-3500	A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Recruiting	USA	0
NCT06177171	Phase I	Decitabine and Cedazuridine + Olaparib	Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors	Recruiting	USA	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT03432897	Phase II	Olaparib	BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337)	Terminated	USA	0
NCT03533946	Phase II	Rucaparib	Rucaparib in Nonmetastatic prOstAte With BRCAness (ROAR)	Terminated	USA	0
NCT03924245	Phase Ib/II	Entinostat Entinostat + Olaparib	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Terminated	USA	0
NCT04586335	Phase I	CYH33 + Olaparib	Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Terminated	USA \| AUS	1
NCT05405309	Phase Ib/II	Olaparib + RP-3500	RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)	Terminated	USA	0
NCT02950064	Phase I	BTP-114	A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Unknown status	USA	0
NCT03925350	Phase II	Niraparib	Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	Unknown status	USA	0
NCT04633902	Phase II	Olaparib + Pembrolizumab	Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	Unknown status	USA	0
NCT03432676	Phase II	Epacadostat + Pembrolizumab	Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)	Withdrawn		0

Showing 1 to 34 of 34 entries

Filter rows:

Profile Name	ATM mutant
Gene Variant Detail	ATM mutant (unknown)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting